Medtronic (NYSE:MDT) said today that it enrolled the 1st European patient in a huge, real-world study of the SuperDimension lung device it acquired along with Covidien early last year. The 2-year, 2,500-patient Navigate trial is designed to evaluate the performance of the LungGPS electromagnetic navigation bronchoscopy technology the SuperDimension device uses to navigate the lungs. The single-arm post-market study […]
Earlier this week a company director, Frederick Moll, picked up another 5,000 shares at $24.15 each, representing the 1st insider buy on the open market since late last year.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Covidien (NYSE:COV) confirmed that it’s agreed to acquire medical device maker superDimension, saying it will pay about $300 million plus possible earnouts in a deal expected to close during the 2nd quarter.
The Mansfield, Mass.-based medical products giant said it plans to integrate superDimension, which makes the i-Logic pulmonology device, into its medical device segment’s endomechanical portfolio.
Covidien (NYSE:COV) is set to close a $350 million buyout of Israeli lung diagnosis firm superDimension by the end of the week, according to Israeli business journal Calcalist.
Founded in Tel Aviv by Pinchas Gilboa, Minneapolis-based superDimension, which employs about 120 people worldwide, also has offices in Dusseldorf, Germany.
MASSDEVICE ON CALL — A team of U.K. researchers is calling for a ban on metal-on-metal hip implants, citing studies that demonstrate that they fail more often than other artificial hips, especially when used in women.
SuperDimension Inc. raised $24.8 million, according to the Globes news service.
The Plymouth, Minn.-based startup, which also has offices in Israel and Germany, is developing GPS-like technology designed to detect early stages of lung cancer. Dubbed electromagnetic navigation bronchoscopy, SuperDimension’s system allows doctors to probe the deepest regions of the lungs, guided by sensors and 3D mapping software.